Online citations, reference lists, and bibliographies.
← Back to Search

Time For More Optimism In Metastatic Breast Cancer?

E. Senkus, F. Cardoso, O. Pagani
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Treatment of metastatic breast cancer has substantially changed in the last decades. Availability of new cytotoxics and targeted therapies as well as changes in treatment philosophy and strategy have all contributed to a significant improvement in both survival and patients' quality of life. The multidisciplinary approach, personalised treatments based on tumour characteristics, patient's and disease history, as well as re-definition of treatment goals, aiming at the lowest possible impact on patients' life by replacing aggressive multidrug chemotherapy with single-agent cytotoxic treatment or endocrine±targeted therapies, have all been the bases of the new treatment paradigm. More recently the development of the international advanced breast cancer (ABC) consensus guidelines have further contributed to this improvement. This review will focus on the major achievements and challenges in the different tumour subtypes and sites, with a focus on future research topics and trends.
This paper references
10.1158/1078-0432.CCR-04-0220
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
T. Nielsen (2004)
10.1200/JCO.2008.19.9844
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
S. Dawood (2010)
10.1002/cncr.22885
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
H. Burstein (2007)
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
C. Osborne (2005)
10.1016/S1040-1741(09)79375-3
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
J. Thigpen (2009)
10.1634/theoncologist.2009-0145
Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
L. Rosen (2010)
10.1016/S0959-8049(12)70687-1
2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747)
S. Johnston (2012)
10.1038/nrc721
Endocrine-responsive breast cancer and strategies for combating resistance
S. Ali (2002)
10.1111/j.1524-4741.2009.00744.x
Randomized Trial Comparing Locoregional Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at the Presentation (Protocol MF07‐01): A Study of Turkish Federation of the National Societies for Breast Diseases
A. Soran (2009)
10.2165/11204810-000000000-00000
Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
Jamie D. Croxtall (2011)
10.1227/NEU.0b013e31820773b2
Trends in Survival After Surgery for Breast Cancer Metastatic to the Brain and Spinal Column in Medicare Patients: A Population-Based Analysis
K. Cahill (2011)
10.1016/J.YOBG.2011.05.178
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
J. S. Dungan (2011)
10.1210/EDRV-13-1-3
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients.
J. Klijn (1992)
10.1093/ANNONC/MDL064
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).
B. Pestalozzi (2006)
10.1200/JCO.2011.39.0708
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
T. Bachelot (2012)
10.1200/JCO.2009.26.5884
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
I. H. Park (2010)
10.1200/jco.2012.30.18_suppl.lba671
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.
F. Boyle (2012)
10.1016/j.breast.2011.02.006
Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative.
N. E. El Saghir (2011)
10.1002/cncr.23930
Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer
N. Lin (2008)
10.1200/JCO.2009.24.9565
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
R. Carlson (2010)
10.1016/S0084-3873(11)00184-2
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
J. Thigpen (2011)
10.1158/0008-5472.SABCS12-S1-6
Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)
R. Finn (2012)
10.1093/ANNONC/MDF013
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
M. Colleoni (2002)
10.1016/S1470-2045(07)70074-8
Triple-negative breast cancer: therapeutic options.
S. Cleator (2007)
10.1158/0008-5472.SABCS11-S5-7
S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.
M. Martín (2011)
10.1016/j.clbc.2012.09.002
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
E. Montagna (2013)
10.2165/11535560-000000000-00000
Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer
P. Blank (2012)
10.1245/s10434-010-1016-1
Metastasectomy and Surgical Resection of the Primary Tumor in Patients With Stage IV Breast Cancer
Barbara A. Pockaj (2010)
10.1056/NEJMRA043186
Trastuzumab--mechanism of action and use in clinical practice.
C. Hudis (2007)
10.3816/CBC.2009.n.005
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
F. Kassam (2009)
10.3322/caac.21166
Cancer statistics, 2013
R. Siegel (2013)
10.1200/JCO.2008.26.15_SUPPL.1062
Observational Demetra study: Survival of metastatic breast carcinoma patients after treatment with trastuzumab
S. Ménard (2008)
10.1016/J.BREASTDIS.2011.03.043
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
K. Gelmon (2011)
10.2174/1871520610909030348
Mechanisms of trastuzumab resistance in breast cancer.
S. Tolaney (2009)
Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
S. Johnston (2005)
10.1016/j.ijsu.2011.01.009
Resection of liver metastases from breast cancer: towards a management guideline.
M. Howlader (2011)
10.1200/JCO.2010.28.0982
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
N. Robert (2011)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
10.1016/S0084-3873(11)00185-4
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
J. Thigpen (2011)
10.1158/0008-5472.SABCS11-P1-17-05
P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.
R. Finn (2011)
10.1038/nrclinonc.2010.119
Whole-brain radiation therapy in breast cancer patients with brain metastases
Cyrus Chargari (2010)
10.1186/bcr2835
Therapeutic targets for bone metastases in breast cancer
P. Clézardin (2011)
10.1200/JCO.2009.25.8707
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
H. Burstein (2010)
10.1158/0008-5472.SABCS10-PD01-01
Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial
J. Baselga (2010)
10.1016/S0140-6736(10)60892-6
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
A. Tutt (2010)
10.1200/JCO.2008.16.2578
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
A. Di Leo (2008)
10.1016/j.breast.2008.03.006
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
A. Fabi (2008)
10.1056/NEJMoa0900212
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
P. Fong (2009)
10.1093/annonc/mds284
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
A. Awada (2013)
10.1016/S0513-5117(09)79092-1
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
J. Uhm (2009)
10.1056/NEJMoa1209124
Trastuzumab emtansine for HER2-positive advanced breast cancer.
S. Verma (2012)
10.1200/JCO.2010.29.7101
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
A. Stopeck (2010)
10.1172/JCI45014
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
B. Lehmann (2011)
10.1016/j.ijrobp.2011.02.019
Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases.
S. Chao (2012)
10.1007/s10637-009-9310-0
Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials
J. Lee (2009)
10.1371/journal.pmed.1000279
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
F. Blows (2010)
10.1007/s11547-011-0634-4
High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results
G. Orgera (2011)
10.1200/JCO.2008.19.5396
Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy.
R. Le Scodan (2009)
10.1093/annonc/mdp447
Activity of fulvestrant in HER2-overexpressing advanced breast cancer.
J. Robertson (2010)
10.1200/JCO.2012.46.1574
Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
Otto Metzger-Filho (2013)
10.1093/ANNONC/MDG483
Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?
A. Jones (2003)
10.2214/AJR.09.3836
Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer.
T. Vogl (2011)
10.1200/JCO.2008.20.6847
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
B. Kaufman (2009)
10.1016/j.breast.2011.07.006
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
J. Huober (2012)
10.1186/1755-8794-4-3
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
C. Fan (2010)
10.1038/nrclinonc.2011.88
Local treatment of metastatic cancer—killing the seed or disturbing the soil?
S. Morgan (2011)
10.1158/1078-0432.CCR-10-2962
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
A. Brufsky (2011)
10.1056/NEJMoa1201622
Combination anastrozole and fulvestrant in metastatic breast cancer.
R. Mehta (2012)
10.1093/annonc/mdp492
Triple-negative breast cancer--current status and future directions.
O. Gluz (2009)
10.1016/S1470-2045(12)70432-1
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
T. Bachelot (2013)
10.1186/1756-9966-30-54
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
F. Cuppone (2011)
10.1002/14651858.CD003370.PUB3
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
L. Gibson (2007)
10.1093/ANNONC/MDL334
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
H. Kennecke (2007)
10.1093/ANNONC/MDL475
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
G. Valabrega (2007)
10.1097/PPO.0b013e3181d24ff7
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
S. Isakoff (2010)
10.1097/CCO.0b013e328347918b
New developments for treatment and prevention of bone metastases
J. Body (2011)
10.1200/JCO.2005.06.081
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
D. Hicklin (2005)
10.1007/s10549-011-1875-6
Beyond taxanes: the next generation of microtubule-targeting agents
J. Cortés (2011)
10.1093/jnci/djp235
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
F. Cardoso (2009)
10.1002/ijc.25516
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
J. Ferlay (2010)
10.1056/NEJMOA072113
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
K. Miller (2007)
10.1634/theoncologist.2009-0029
Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study
Jean-Marc Extra (2010)
10.1186/1471-2407-7-134
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
M. Tischkowitz (2007)
10.1200/JCO.2009.23.3734
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
S. Johnston (2009)
10.1007/s10549-009-0655-z
Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy
J. Sparano (2009)
10.1158/1078-0432.CCR-09-1823
New Strategies in Estrogen Receptor–Positive Breast Cancer
S. Johnston (2010)
10.1007/s10549-012-2192-4
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
J. Robertson (2012)
10.1007/s10549-009-0498-7
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
K. Inoue (2009)
10.1016/J.YONC.2011.10.003
Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies
N. Fuente (2011)
10.1634/theoncologist.2009-0240
Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
L. Schwartzberg (2010)
10.1016/J.IJROBP.2007.03.056
Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer.
D. Coldwell (2007)
10.1200/JCO.2001.19.2.343
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
J. Klijn (2001)
10.1200/JCO.1996.14.10.2738
Annual hazard rates of recurrence for breast cancer after primary therapy.
T. Saphner (1996)
10.1016/J.YONC.2012.08.018
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
J. Thigpen (2012)
10.1016/j.ctrv.2012.06.011
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women.
F. Cardoso (2013)
10.1007/s10549-009-0670-0
Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature
J. Ruiterkamp (2009)
10.3171/2010.8.JNS10461
Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article.
D. Kondziolka (2011)
10.1200/JCO.2008.21.6457
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
D. Miles (2010)
10.1200/JCO.2011.38.1095
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
J. Bergh (2012)
10.1093/jnci/djq029
International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?
O. Pagani (2010)
10.1016/J.EJCA.2007.11.007
Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer
O. Young (2008)
10.1200/JCO.2010.28.8415
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
A. Di Leo (2010)
10.1007/s10549-010-0985-x
Re-searching anthracycline therapy
C. Oakman (2010)
10.1007/s11060-009-0062-7
The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
M. Mehta (2009)
10.1200/JCO.2010.30.8213
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
M. Andersson (2011)
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in 226 E
JG Klijn (2014)
10.1016/J.YONC.2012.08.009
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
J. Thigpen (2012)
AMeta-Analysis on the Interaction between HER-2 Expression and Response to EndocrineTreatment in Advanced Breast Cancer
M. Laurentiis (2005)
10.1002/14651858.CD008941.pub2
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
A. D. Wagner (2012)
10.4161/cbt.11.9.15045
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Joan T. Garrett (2011)
10.1093/jnci/djp082
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
M. Cheang (2009)
10.1016/S1470-2045(11)70214-5
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
K. Gelmon (2011)
10.1200/JCO.2009.25.9820
Metastatic behavior of breast cancer subtypes.
H. Kennecke (2010)
10.1016/j.ejca.2012.03.002
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
R. Bartsch (2012)
10.1016/j.breast.2010.11.008
Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
S. Goel (2011)
10.1093/JNCI/95.2.142
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
G. Konecny (2003)
10.1016/s0923-7534(20)34361-1
Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)
X. Pivot (2012)
Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: A prospective study using quality-of-life assessment.
G. Cheung (2006)
10.1016/j.clbc.2011.03.003
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
P. Hamberg (2011)
10.1007/s11060-011-0629-y
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
N. Lin (2011)
10.1186/bcr2642
Antiangiogenic therapy for breast cancer
D. Nielsen (2010)
10.1200/JCO.2011.29.15_SUPPL.1007
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
J. O'Shaughnessy (2011)
10.2146/ajhp070629
Projecting future drug expenditures--2008.
J. Hoffman (2008)
10.1007/s10549-008-0086-2
Pattern of metastatic spread in triple-negative breast cancer
R. Dent (2008)
10.1634/theoncologist.2010-0278
In the end what matters most? A review of clinical endpoints in advanced breast cancer.
S. Verma (2011)
10.1158/0008-5472.SABCS12-P5-18-26
Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)
S. Swain (2012)
10.1634/theoncologist.2012-0448
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
S. Swain (2013)
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
L. Celio (1999)
10.1007/s10549-007-9885-0
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
D. Cameron (2007)
10.1200/jco.2009.27.15_suppl.1004
Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.
R. Swaby (2009)
10.1016/j.ejca.2008.09.034
What is triple-negative breast cancer?
W. Irvin (2008)
10.1016/S1040-1741(12)00202-3
Liver resection and local ablation of breast cancer liver metastases – A systematic review
T. A. Aloia (2012)
Cetuximab + cisplatin in estrogen receptornegative , progesterone receptornegative , HER 2negative ( triplenegative ) metastatic breast cancer : results of the randomized phase II BALI1 trial
J Baselga (2010)
10.1016/j.breast.2012.03.003
1st International consensus guidelines for advanced breast cancer (ABC 1).
F. Cardoso (2012)
10.1007/s10549-008-0101-7
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
A. Bafford (2008)
Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer
C. Poznak (2013)
10.1200/JCO.2007.12.3588
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
N. Lin (2008)
10.1038/nrclinonc.2011.44
Oligometastases revisited
R. Weichselbaum (2011)
10.1007/s10549-009-0727-0
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
A. Valachis (2009)
10.1200/JCO.2008.21.4437
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
K. Blackwell (2010)
10.1158/0008-5472.CAN-07-5644
Subtypes of breast cancer show preferential site of relapse.
M. Smid (2008)
10.1007/s10147-011-0260-0
Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer
N. Hayashi (2011)
10.1093/jnci/djp369
Detecting an overall survival benefit that is derived from progression-free survival.
K. Broglio (2009)
10.1016/J.HOC.2007.03.005
Emerging targeted therapies for breast cancer.
M. Johnson (2005)
10.1200/JCO.2011.38.3331
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
A. Wolff (2013)
10.1007/s10549-012-2003-y
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
N. Lin (2012)



This paper is referenced by
10.4172/2155-9619.1000271
The Impact of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value and Neutrophil/Lymphocyte Ratio (NLR) in Predicting Prognosis in Surgically Treated Oligometastatic Breast Cancer Patients
Hala A El-Lathy (2016)
10.2147/IJN.S256898
Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy
F. Aleanizy (2020)
10.22034/APJCP.2017.18.10.2673
Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
G. D. dos Santos (2017)
10.1007/s12254-018-0426-9
Cure in metastatic breast cancer
T. Westphal (2018)
10.1016/j.clbc.2014.10.007
Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer.
J. Shaughnessy (2015)
10.1093/annonc/mdy517
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams (2019)
10.4081/oncol.2019.425
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review
Gilbert Lazarus (2019)
10.1016/j.ijbiomac.2019.10.015
Neem gum based pH responsive hydrogel matrix: A new pharmaceutical excipient for the sustained release of anticancer drug.
Priyanka Mankotia (2019)
Exploring the role of Interleukin-6 and other host-associated factors in tumor progression and metastasis development
Maria do Rosário André (2017)
10.1016/j.jos.2017.04.011
The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment.
E. Nakata (2017)
10.7314/APJCP.2014.15.22.9673
Exploring factors related to metastasis free survival in breast cancer patients using Bayesian cure models.
T. Jafari-Koshki (2014)
10.1021/acs.jmedchem.5b00753
Virtual High-Throughput Screening To Identify Novel Activin Antagonists.
J. Zhu (2015)
Hormone Resistance as a Treatment Target for Breast CancerRuiz-Borrego*
Manuel Ruíz-Borrego (2014)
DIFFERENT APPROACHES TO DEVELOP RADIO-AND CHEMOTHERAPY FOR TREATMENT OF HUMAN CANCER
Manoj (2014)
10.1038/srep36173
In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling
S. Mollard (2016)
10.1007/s11306-014-0723-1
Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden
P. Dowling (2014)
10.1159/000358750
Oligometastatic Breast Cancer: A Shift from Palliative to Potentially Curative Treatment?
S. Di Lascio (2014)
10.1590/MEDICC.2018.20010008
Brain Metastases in Havana Cancer Patients
Joel Caballero-García (2018)
10.18632/oncotarget.13522
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy
Chiara D'Avino (2016)
Predicción de la respuesta al tratamiento con Paclitaxel semanal y Bevacizumab en mujeres con cáncer de mama diseminado a través de un perfil de expresión génica
V. M. Marín (2015)
Peptide and monoclonal antibody mediated targeting of nanoconjugates in cancer chemotherapy
H. Kulhari (2015)
Targeting cFLIP to inhibit residual cancer stem cells after chemotherapy
T. Robinson (2017)
10.18632/oncotarget.14735
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
C. Bighin (2017)
10.15405/EPSBS.2016.07.02.22
Reproductive concerns and psychosocial adjustment of young breast and gynecologic cancer patients
M. J. Candido (2016)
10.1016/j.canlet.2017.01.027
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
E. Montagna (2017)
10.1016/j.bbacli.2014.08.004
Transferrin-bound proteins as potential biomarkers for advanced breast cancer patients
P. Dowling (2014)
10.1007/s11705-016-1553-7
Antioxidant and antitumor effects and immunomodulatory activities of crude and purified polyphenol extract from blueberries
X. Kou (2016)
10.1016/J.SCIB.2017.05.022
A CD44-biosensor for evaluating metastatic potential of breast cancer cells based on quartz crystal microbalance
Xiaojuan Yang (2017)
10.1007/978-3-319-48848-6_44
Treatment of Advanced Disease: Guidelines
Rosário André (2017)
10.1007/978-1-4939-9220-1_14
Monoclonal Antibody-Conjugated Dendritic Nanostructures for siRNA Delivery.
H. Kulhari (2019)
10.1016/j.canlet.2019.01.023
RLIP inhibition suppresses breast-to-lung metastasis.
J. Singhal (2019)
10.3892/ol.2017.6852
Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer
X. Lin (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar